Vera Therapeutics, Inc.(VERA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VERA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Vera Therapeutics, Inc. (VERA), a Healthcare sector company. VERA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Vera Therapeutics, Inc. reports net income of $-109.5M, free cash flow of $-100.3M. Top institutional holders of VERA by reported 13-F value include BlackRock, Avoro Capital Advisors, STATE STREET, based on the most recent SEC filings. VERA trades on the Nasdaq exchange and files with the SEC under CIK 1831828. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VERA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vera Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-109.5M
Free Cash Flow
Q2 2026
$-100.3M
D/E Ratio
Q2 2026
0.18
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-96.9% YoYOperating Income
-88.7% YoYEPS (Diluted)
-69.5% YoYTotal Assets
+12.1% YoYTotal Debt
+47.6% YoYOp. Cash Flow
-79.0% YoYFree Cash Flow
-78.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-299.6M -96.9% | $-152.1M -58.5% | $-96.0M -7.8% | $-89.1M -173.1% | $-32.6M +38.9% | $-53.4M |
| Operating Income | $-315.5M -88.7% | $-167.2M -63.9% | $-102.0M -12.2% | $-90.9M -164.2% | $-34.4M +34.1% | $-52.2M |
| EPS (Diluted) | $-4.66 -69.5% | $-2.75 -22.2% | $-2.25 +32.8% | $-3.35 -37.9% | $-2.43 | — |
| Total Assets | $734.7M +12.1% | $655.7M +273.5% | $175.5M +33.6% | $131.4M +56.9% | $83.7M +53.5% | $54.6M |
| Total Debt | $74.8M +47.6% | $50.7M +1.6% | $49.9M +101.0% | $24.8M +404.0% | $4.9M | $0.00 |
| Operating Cash Flow | $-241.1M -79.0% | $-134.7M -46.1% | $-92.2M -36.4% | $-67.6M -185.1% | $-23.7M +31.9% | $-34.8M |
| Free Cash Flow | $-241.7M -78.2% | $-135.7M -47.1% | $-92.2M -36.3% | $-67.7M -185.4% | $-23.7M +32.1% | $-34.9M |
Get alerted when VERA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Vera Therapeutics, Inc. including:
Top Institutional Holders of VERA
BlackRock, Inc.
$246.6M5,747,760 shAvoro Capital Advisors LLC
$245.6M5,723,888 shSTATE STREET CORP
$178.0M4,148,786 shPRICE T ROWE ASSOCIATES INC /MD/
$172.2M4,012,936 shDeep Track Capital, LP
$171.6M4,000,000 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$168.1M3,916,400 shKynam Capital Management, LP
$124.0M2,890,059 shMORGAN STANLEY
$120.1M2,799,459 shSofinnova Ventures Inc
$119.9M2,793,987 shFMR LLC
$119.0M2,774,070 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $246.6M | 5,747,760 |
| Avoro Capital Advisors LLC | $245.6M | 5,723,888 |
| STATE STREET CORP | $178.0M | 4,148,786 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $172.2M | 4,012,936 |
| Deep Track Capital, LP | $171.6M | 4,000,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $168.1M | 3,916,400 |
| Kynam Capital Management, LP | $124.0M | 2,890,059 |
| MORGAN STANLEY | $120.1M | 2,799,459 |
| Sofinnova Ventures Inc | $119.9M | 2,793,987 |
| FMR LLC | $119.0M | 2,774,070 |
More Healthcare Companies
View all Healthcare →Put VERA on your watchlist
Track score changes the day Vera Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VERA a good stock to buy?
13F Pro's AI-powered analysis of Vera Therapeutics, Inc. (VERA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VERA are available on the VERA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VERA is classified as a mid company.
Which hedge funds own VERA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VERA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vera Therapeutics, Inc.'s investment landscape.